Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Stock Information for Precigen Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Precigen Inc.

Precigen Reports First Quarter 2025 Financial Results and Business Updates
Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock
Precigen Reports Third Quarter 2024 Financial Results and Business Updates
Precigen to Participate in the Stifel 2024 Healthcare Conference
Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.